GLS and breast carcinoma: A similar glutaminase inhibitor, CB-839 (Calithera Biosciences, Inc., South San Francisco, CA) was recently shown to display significant antitumor activity in two xenograft models of triple negative and basal-like HER2-positive breast cancer as a single agent and in combination with paclitaxel chemotherapy [16].